Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
May 19th, 2018
9.8K views
The protocol presented here describes a platform for identifying small molecules for the treatment of liver disease. A step-by-step description is presented detailing how to differentiate iPSCs into cells with hepatocyte characteristics in 96-well plates, and to use the cells to screen for small molecules with potential therapeutic activity.
Overview
This protocol outlines a method for differentiating human induced pluripotent stem cells (iPSCs) into hepatocyte-like cells suitable for high-throughput screening. This approach enables the identification of small molecules that may serve as treatments for liver disease.
Key Study Components
Area of Science
- Stem Cell Biology
- Liver Disease Research
- High-Throughput Screening
Background
- Liver cells are challenging to culture in vitro.
- iPSCs can be generated from patients, providing a personalized model of liver disease.
- This method allows for the generation of unlimited hepatocyte-like cells.
- The technique is accessible even to those with limited stem cell knowledge.
Purpose of Study
- To develop a reliable method for generating hepatocyte-like cells from iPSCs.
- To create a platform for screening potential therapeutic compounds for liver disease.
- To facilitate research into liver disease treatments using patient-derived cells.
Methods Used
- Differentiation of iPSCs into hepatocyte-like cells.
- Utilization of 96-well plates for high-throughput screening.
- Screening small molecules for therapeutic activity.
- Demonstration of the protocol by researchers.
Main Results
- Successful differentiation of iPSCs into functional hepatocyte-like cells.
- Establishment of a reproducible screening platform.
- Identification of small molecules with potential therapeutic effects.
- Demonstration of ease of use for researchers.
Conclusions
- The protocol provides a valuable tool for liver disease research.
- It enables personalized medicine approaches by using patient-derived cells.
- This method can significantly advance the search for liver disease treatments.
Frequently Asked Questions
What are induced pluripotent stem cells (iPSCs)?
iPSCs are cells that have been genetically reprogrammed to an embryonic stem cell-like state, allowing them to differentiate into various cell types.
Why is it important to generate hepatocyte-like cells?
Hepatocyte-like cells are crucial for studying liver function and disease, as they can mimic the characteristics of actual liver cells.
How does high-throughput screening work?
High-throughput screening allows researchers to quickly test thousands of compounds for their effects on cells, facilitating drug discovery.
What are the advantages of using patient-derived cells?
Patient-derived cells can better replicate individual disease characteristics, leading to more personalized and effective treatment strategies.
Is this protocol suitable for researchers with limited experience?
Yes, the protocol is designed to be straightforward and accessible, even for those without extensive knowledge of stem cell biology.
Executive Industry Relevance
Human iPSC-derived hepatocyte-like cells (HLCs) enable scalable, patient-specific platforms for high-throughput compound screening in liver disease research. This approach addresses the challenge of limited primary hepatocyte availability and supports predictive confidence in early-stage drug discovery. The platform's reproducibility and compatibility with 96-well formats position it as a critical asset for portfolio triage and mechanistic de-risking in hepatic target validation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of disease-relevant hepatic pathways using patient-derived cells.
- Supports functional target validation by modeling inborn errors of hepatic metabolism.
- Facilitates mechanistic de-risking through reproducible differentiation and phenotypic fidelity.
- Improves predictive confidence for advancing hepatic targets in the discovery pipeline.
Screening & Assay Development
- Provides a standardized, high-throughput compatible system for compound screening.
- Delivers quantitative outputs, such as APOB levels, for robust hit identification.
- Ensures reproducibility across wells, supporting assay scalability and platform reuse.
- Enables reliable evaluation of compound effects on hepatocyte function and viability.
Translational & Preclinical Research
- Aligns with disease-relevant models by using patient-specific iPSCs for translational continuity.
- Supports risk-adjusted advancement decisions by linking in vitro findings to hepatic disease phenotypes.
- Facilitates identification of translational biomarkers, such as APOB, for preclinical validation.
- Reduces late-stage biological risk by enabling early mechanistic insights in human-derived systems.
Pipeline & Workflow Integration
This platform integrates from early discovery through lead identification, enabling seamless transition to preclinical research for liver-targeted therapeutics.
- Discovery Biology: Supports hypothesis testing and pathway clarification in hepatic disease models.
- Screening: Delivers assay readiness and reproducibility for high-throughput compound evaluation.
- Analytics: Provides quantitative readouts, such as APOB z-scores, for comparative analysis.
- Translational Research: Bridges discovery and preclinical validation using patient-derived hepatocyte-like cells.
- Enterprise Reuse: Offers a scalable, reusable platform for diverse hepatic drug discovery programs.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence and target validation in hepatic drug discovery.
- Operational Value: Standardizes workflows and enables reproducible, scalable screening.
- Strategic Value: Improves go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of liver disease programs.
Implementation Considerations
- Requires expertise in iPSC culture and hepatic differentiation protocols.
- Needs access to 96-well plate infrastructure and quantitative assay platforms.
- Demands cross-team standardization for reproducibility and data comparability.
- Adaptation may be needed for different patient-derived iPSC lines or disease models.
- Daily medium preparation and component stability are critical for differentiation fidelity.
Biopharma FAQs
Why does null hypothesis testing matter for APOB-lowering compound screens?
Null hypothesis testing ensures that observed reductions in APOB levels are statistically significant and not due to random variation, supporting robust target validation in hepatic drug discovery. This statistical rigor underpins confidence in hit identification and downstream decision-making. It is essential for distinguishing true compound effects from background noise in high-throughput screens.
How does independent variable isolation fit the iPSC-HLC screening workflow?
Isolating variables such as compound concentration and treatment duration allows researchers to attribute changes in APOB or cell viability directly to specific interventions. This clarity is critical for mechanistic de-risking and for optimizing screening conditions. It supports reproducible and interpretable results across discovery teams.
What do quantitative APOB measurements enable in compound evaluation?
Quantitative APOB measurements provide objective, scalable endpoints for assessing compound efficacy in lowering hepatic biomarkers. These outputs enable z-score analysis and facilitate high-throughput hit triage. They also support cross-comparison of compound performance within and across screening campaigns.
Why are replication requirements important for cross-functional screening teams?
Replication ensures that compound effects on APOB and cell viability are consistent and reproducible across wells and plates, which is vital for cross-team data integration. This reliability underpins collaborative decision-making and portfolio advancement. It also reduces the risk of false positives or negatives in screening outputs.
What statistical analysis capabilities are required before implementing APOB screens?
Teams must be able to calculate z-factors, perform z-score analysis, and assess assay reproducibility to validate screening quality. These capabilities confirm that the platform meets industry standards for high-throughput drug discovery. Robust statistical analysis is essential for confident hit identification and downstream validation.
Chapters in this video
0:04
Title
1:05
Culture of Human Induced Pluripotent Stem Cells
3:39
Differentiation of Human iPSCs to Hepatocyte-like Cells and Small Molecule Screening
9:34
Results: Differentiation of iPSCs and Identification of Small Molecules for Drug Discovery
11:12
Conclusion
